Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

30%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

4(40.0%)

Phase 3

2(20.0%)

Phase 2

2(20.0%)

Phase 4

1(10.0%)

Phase 1

1(10.0%)

10Total

N/A(4)

Phase 3(2)

Phase 2(2)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07405216Phase 4Recruiting

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

Role: lead

NCT07483697Not ApplicableNot Yet Recruiting

Multimodal Intervention for Early Chronic Kidney Disease in Young People: Dysbiosis and Inflammation (CKD)

Role: lead

NCT07430280Not ApplicableNot Yet Recruiting

Synbiotic Supplementation and Inflammation in Predialysis Chronic Kidney Disease

Role: lead

NCT07406971Phase 2Recruiting

Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke

Role: collaborator

NCT04215692Not ApplicableSuspended

Lung Ultrasound-guided Fluid Therapy in Pediatric Intensive Care Unit Patients

Role: collaborator

NCT05543837Phase 2Completed

Capsaicin for Cerebral Perfusion Augmentation

Role: collaborator

NCT04333602Not ApplicableCompleted

Asymptomatic Bacteriuria in Early Kidney Transplantation Follow up

Role: lead

NCT04381858Phase 3Completed

Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia

Role: lead

NCT04391127Phase 3Completed

Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection

Role: lead

NCT04545892Phase 1Completed

Capsaicin for Cerebral Perfusion Augmentation.

Role: collaborator

All 10 trials loaded